A new biotech licensing Chinese drugs with a unique approach gets high-profile backing

A new startup hoping to source the best therapies being developed in China and bring them stateside has secured early funding from Venrock and BVF Partners.

Expedition Therapeutics has raised an undisclosed amount of seed financing from Venrock, BVF Partners, and Chinese VC firm Lake Bleu Capital. It plans to raise a Series A round once the team has licensed its first batch of drugs, according to founder and CEO Yi Larson.

In particular, Larson is interested in immune and inflammatory disease treatments, as well as bispecific antibody therapies.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Delayed puberty in boys could lead to new follow-up healthcare routines in the future

Swedish young men who went through late puberty during adolescence are more likely to use healthcare services later in life, according to research presented at

November 18, 2024

Sanofi shakes up clinical plans for trio of programs from Denali, Principia and Kymab deals

Sanofi is shuffling its pipeline after several trial flops in anti-inflammatory and cancer drugs it landed through a partnership with Denali and buyouts of Principia

October 28, 2023

Save the Food and Drug Administration by breaking it up

The U.S. Food and Drug Agency is not really a singular agency. In practice, it operates more like five or more “FDAs” — each covering drugs, devices,

January 2, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.